Otto F. Metzger
Oncology
450 Brookline Avenue
Susan F. Smith Center For Women's Cancers
Boston, MA 02115
Susan F. Smith Center For Women's Cancers
Boston, MA 02115
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Palbociclib for HR-Positive, HER2-Positive Breast Cancer. Reply.
Journal: The New England journal of medicine
Published: April 29, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: January 28, 2026
Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 27, 2025
Circulating tumor DNA in neoadjuvant endocrine therapy for early breast cancer.
Journal: ESMO open
Published: August 21, 2025
Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care.
Journal: Breast cancer research and treatment
Published: August 15, 2025
Awareness, Knowledge, and Treatment Patterns of Nonmetastatic Inflammatory Breast Cancer in Low- and Middle-Income Countries: The BRIDGES Study.
Journal: JCO global oncology
Published: December 20, 2024
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.
Journal: Cell genomics
Published: December 03, 2024
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).
Journal: ESMO open
Published: November 14, 2024
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).
Journal: Breast cancer research : BCR
Published: June 20, 2024
Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium.
Journal: The Lancet regional health. Europe
Published: March 29, 2024
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer.
Journal: ESMO open
Published: March 04, 2024
Last Updated: 09/26/2026